Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue

-- Non-GAAP Diluted EPS Rises 15% and GAAP Diluted EPS Up 28% --

-- Preparing for BG-12 Filing in First Half of 2012 --

-- Phase III data Anticipated in 2012 for Long-Lasting Factor VIII and Factor IX in Hemophilia and Dexpramipexole in ALS --

WESTON, Mass.--(BUSINESS WIRE)--Jan 31, 2012 - Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

Full Year 2011 Highlights:

  • Total revenues in 2011 increased 7% to $5.0 billion year-over-year. TYSABRI® (natalizumab) revenues increased 20% year-over-year to $1.1 billion while AVONEX® (interferon beta-1a) revenues increased 7% year-over-year to $2.7 billion. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $1.0 billion for the year, a decrease of 7% versus prior year as a result of certain royalties from individual countries expiring and a charge of approximately $50 million from an accrual relating to Genentech's arbitration with Hoechst GmbH.
  • Global in-market sales of TYSABRI for the full year of 2011 were $1.5 billion, an increase of 23% over 2010. The total was comprised of $747 million in U.S. sales and $764 million in sales outside the U.S.
  • On a reported basis, calculated in accordance with accounting principles generally accepted in the U.S. (GAAP), full year 2011 GAAP diluted EPS were $5.04, an increase of 28% versus 2010. GAAP net income attributable to Biogen Idec for the year was $1.2 billion, an increase of 23% versus 2010.
  • Non-GAAP diluted EPS for 2011 were $5.90, an increase of 15% over 2010. Non-GAAP net income attributable to Biogen Idec for 2011 was $1.4 billion, an increase of approximately 10% versus 2010.

Fourth Quarter 2011 Highlights:

 

  • Fourth quarter revenues increased 9% to $1.3 billion, compared to the fourth quarter of 2010. TYSABRI revenues increased 11% year-over-year to $269 million while AVONEX revenues increased 8% year-over-year to $703 million. RITUXAN revenues from our unconsolidated joint business arrangement were $258 million for the quarter, approximately in-line with the prior year.
  • Global in-market sales of TYSABRI in the fourth quarter of 2011 were $380 million, an increase of 14% over the fourth quarter of 2010. The total was comprised of $196 million in U.S. sales and $183 million in sales outside the U.S.
  • Fourth quarter 2011 GAAP diluted EPS were $1.22, an increase of 23% over the fourth quarter of 2010. GAAP net income attributable to Biogen Idec for the quarter was $300 million, an increase of 25% from the fourth quarter of 2010.
  • Non-GAAP diluted EPS for the fourth quarter of 2011 were $1.51, an increase of 6% over the fourth quarter of 2010. Non-GAAP net income attributable to Biogen Idec for the fourth quarter of 2011 was $370 million, an increase of approximately 7% from the fourth quarter of 2010. A reconciliation of our GAAP to non-GAAP results is included on Table 3 within this press release.

As of December 31, 2011, Biogen Idec had cash, cash equivalents and marketable securities of approximately $3.1 billion.

"Our success in 2011 gives us a strong position on which to build," said George A. Scangos, Ph.D., the company's chief executive officer. "In 2012 we will focus on the continued growth and leadership of our marketed products and the advancement of our strong pipeline. We will continue to work on risk stratification to unlock the value of TYSABRI and we plan to launch the AVONEX PEN in the US to support the continued growth of AVONEX. We are working to file BG-12 as quickly as possible, and are preparing for the potential launch of the product. We also anticipate phase III data later this year for our long-acting factor VIII and factor IX in hemophilia, and dexpramipexole in ALS, and are preparing for multiple filings and product launches where the data are positive. At the same time we are working to strengthen our early stage pipeline through internal research and strategic collaborations to build a foundation for growth and innovation over the long term."

TYSABRI Patient Growth

Based upon data available to us through the TOUCH® prescribing program and other third-party sources, as of the end of December 2011, we estimate that approximately 64,400 patients were on commercial and clinical TYSABRI therapy worldwide, and that cumulatively approximately 95,300 patients have ever been treated with TYSABRI in the post-marketing setting.

Other Products and Royalties

For the full year, revenues from other products were $70 million, an increase of 36% versus 2010. Revenues from other products in the fourth quarter of 2011 were $24 million, compared to $14 million in the fourth quarter of 2010.

Table 4 provides individual product revenues.

Royalties in 2011 increased 15% to $158 million, versus 2010. Royalties were $53 million in the fourth quarter of 2011, an increase of 16% compared to the fourth quarter of 2010.

Corporate partner revenues for the full year of 2011 were $57 million, compared to $32 million in 2010. For the fourth quarter of 2011, corporate partner revenues were $20 million, compared to $6 million in 2010.

2012 Financial Guidance

Biogen Idec also released its full year 2012 financial guidance. This guidance consists of the following components:

 

  • Revenue growth is expected to be in the low to mid-single digits versus 2011.
  • Cost of Sales is expected to be approximately 9% to 10% of total revenue.
  • R&D is expected to be approximately 24% to 25% of total revenue.
  • SG&A is expected to be approximately 22% to 23% of total revenue.
  • Tax rate is expected to be approximately 24% to 26% of pretax income.
  • Non-GAAP diluted EPS is expected to be between $6.10 and $6.20.
  • GAAP diluted EPS is expected to be between $5.46 and $5.56.
  • Capital expenditures are expected to be in the range of $230 to $250 million.

Biogen Idec may incur charges, realize gains or experience other events in 2012 that could cause actual results to vary from this guidance.

Recent Events

 

  • On January 30, 2012, Biogen Idec announced Kenneth DiPietro joined Biogen Idec as Executive Vice President of Human Resources and a member of our executive management team. Mr. DiPietro joined Biogen Idec from Lenovo Group, where he served as Senior Vice President, Human Resources. He has 30 years of experience serving in a range of human resource and general management positions at companies including Microsoft Corporation, Dell Inc. and PepsiCo.
  • On January 26, 2012, Biogen Idec and Elan Corporation announced a global Phase IIIb study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis (SPMS). According to the National Multiple Sclerosis Society, approximately half of all people initially diagnosed with relapsing-remitting multiple sclerosis (RRMS) - the most common form of multiple sclerosis (MS) - will transition to SPMS within 19 years.
  • On January 20, 2012, Biogen Idec and Elan Corporation announced the U.S. Food and Drug Administration (FDA) approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help physicians and people with MS make personalized treatment decisions when considering TYSABRI, a highly effective treatment for relapsing forms of MS.
  • On January 4, 2012, Biogen Idec and Isis Pharmaceuticals announced they entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis' antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy (SMA). Biogen Idec has the option to develop and commercialize this promising compound for the most common genetic cause of infant mortality and will offer its expertise in neurology to aid in rapid development.
  • On December 5, 2011, Samsung and Biogen Idec announced they entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

Conference Call and Webcast

The company's earnings conference call for the fourth quarter will be broadcast via the internet at 8:00 a.m. ET on January 31, 2012, and will be accessible through the Investors section of Biogen Idec's homepage, www.biogenidec.com. Supplemental information in the form of a slide presentation will also be accessible at the same location on the internet at the time of the earnings conference call and will be available there subsequently for one month.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Safe Harbor

This press release contains forward-looking statements, including statements about the anticipated development, timing and therapeutic scope of programs in our clinical pipeline, regulatory filings, prospects for growth, potential product launches and financial guidance. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including our dependence on our three principal products, AVONEX, RITUXAN and TYSABRI, the importance of TYSABRI's sales growth, uncertainty of success in commercializing other products, product competition, the occurrence of adverse safety events with our products, changes in the availability of reimbursement for our products, adverse market and economic conditions, our dependence on collaborations and other third parties over which we may not always have full control, failure to execute our growth initiatives, failure to comply with government regulation, our ability to protect our intellectual property rights, and have sufficient rights to market our products and services, and the cost of doing so, the risks of doing business internationally, problems with our manufacturing processes and our reliance on third parties, charges and other costs relating to our properties, fluctuations in our effective tax rate, our ability to attract and retain qualified personnel, product liability claims, fluctuations in our operating results, the market, interest and credit risks associated with our portfolio of marketable securities, our level of indebtedness, environmental risks, change of control provisions in our collaborations, representation of activist shareholders on our board of directors, and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.

These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

 
TABLE 1
Biogen Idec Inc.
December 31, 2011
Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)
                                     
  Three Months Ended         Twelve Months Ended
  December 31,         December 31,
  2011   2010         2011   2010
REVENUES                                    
                                     
Product $ 996,555     $ 909,752      

 

 

 

  $ 3,836,117     $ 3,470,056  
                                     
Unconsolidated joint business   257,543       257,963      

 

 

 

    996,597       1,077,244  
                   

 

                 
Royalties   52,686       45,328      

 

 

 

    158,497       137,401  
                                     
Corporate partner   19,926       6,029      

 

 

 

 

 

  57,423       31,722  
                                     
Total revenues   1,326,710       1,219,072      

 

 

 

    5,048,634       4,716,423  
                                     
COST AND EXPENSES                                    
                                     
Cost of sales, excluding amortization of acquired intangible assets   139,638       100,304      

 

 

 

    466,780       400,262  
                                     
Research and development   338,933       290,846      

 

 

 

    1,219,602       1,248,604  
                                     
Selling, general and administrative   283,916       276,393      

 

 

 

    1,056,133       1,031,540  
                                     
Collaboration profit sharing   73,453       67,831      

 

 

 

    317,771       258,071  
                                     
Amortization of acquired intangible assets   50,866       53,360      

 

 

 

    208,566       208,928  
                                     
Fair value adjustment of contingent consideration   30,165       -             36,065       -  
                                     
Restructuring charge   636       75,153      

 

 

 

    19,026       75,153  
                                     
Acquired in-process research and development   -       -             -       244,976  
                                     
Total cost and expenses   917,607       863,887      

 

 

 

    3,323,943       3,467,534  
                                     
Income from operations   409,103       355,185      

 

 

 

    1,724,691       1,248,889  
                                     
Other income (expense), net   (3,973 )     (4,664 )    

 

 

 

    (13,477 )     (18,983 )
                                     
INCOME BEFORE INCOME TAX EXPENSE   405,130       350,521      

 

 

 

    1,711,214       1,229,906  
                                     
Income tax expense   104,919       78,768      

 

 

 

    444,528       331,333  
                                     
NET INCOME $ 300,211     $ 271,753      

 

 

 

  $ 1,266,686     $ 898,573  
                                     
Net income attributable to noncontrolling interest, net of tax   (27 )     31,475      

 

 

 

    32,258       (106,700 )
                                     
NET INCOME ATTRIBUTABLE TO BIOGEN IDEC INC. $ 300,238     $ 240,278      

 

 

 

  $ 1,234,428     $ 1,005,273  
                                     
                                     
BASIC EARNINGS PER SHARE $ 1.24     $ 1.00      

 

 

 

  $ 5.09     $ 3.98  
                                     
DILUTED EARNINGS PER SHARE $ 1.22     $ 0.99      

 

    $ 5.04     $ 3.94  
                                     
                                     
WEIGHTED-AVERAGE SHARES USED IN CALCULATING:                                    
BASIC EARNINGS PER SHARE   242,959       239,682      

 

      242,395       252,307  
                                     
DILUTED EARNINGS PER SHARE   245,382       242,937                        

Posted: January 2012


View comments

Hide
(web1)